69 completed. 69 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 69 | Completed 69 |
| Phase 2 | 13 | Completed 13 |
Follow Chronic Obstructive Pulmonary Disease: new trials by email Literature Review of Chronic Obstructive Pulmonary Disease trials Research Report on Chronic Obstructive Pulmonary Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 48 | 2025-02-11 | 2025-08-15 |
| Evaluation the Safety of hemay005 Tablets Hemay005 tablet, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Anhui Hemay Pharmaceutical Co., Ltd | 468 | 2024-12-25 | 2025-12-09 |
| A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2024-05-22 | 2024-10-29 |
| A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 42 | 2024-04-29 | 2025-08-13 |
| Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers CHF6001 DPI, Erythromycin - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 24 | 2024-03-28 | 2024-07-03 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects Ensifentrine - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Nuance Pharma (shanghai) Co., Ltd | 28 | 2023-03-06 | 2023-04-24 |
| Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients HRS-9821 - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 106 | 2023-01-12 | 2025-07-24 |
| A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 108 | 2022-10-11 | 2025-08-22 |
| Clinical Trial Comparing the Pharmacological Effects of EP395 With Placebo in Healthy Adults EP395, Placebo - Chronic Obstructive Pulmonary Disease, COPD | Phase 1 | Completed | EpiEndo Pharmaceuticals | 49 | 2022-10-11 | 2026-04-29 |
| PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers CH6001 - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 44 | 2022-07-29 | 2023-01-26 |
| Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal) - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 108 | 2022-07-29 | 2025-08-28 |
| Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects CHF6001 - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 44 | 2022-05-05 | 2024-04-15 |
| Pharmacokinetic Study to Compare Itepekimab Exposure When Administered With an Autoinjector Versus Prefilled Syringe Itepekimab AI, Itepekimab PFS - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Sanofi | 90 | 2021-09-16 | 2024-09-19 |
| Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast) CHF6001 DPI, Itraconazole - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 24 | 2021-02-22 | 2021-05-05 |
| Mesenchymal Stem Cells in the Treatment of Subjects With Advance Chronic Obstructive Pulmonary Disease (COPD) Mesenchymal Stem Cells - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Mayo Clinic | 15 | 2020-01-06 | 2025-11-14 |
| A Scintigraphy Study of PT010 in COPD Patients BGF-MDI - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 18 | 2019-04-04 | 2021-02-12 |
| PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians Therapeutic Dose 1, Therapeutic Dose 2, Supra-therapeutic Dose - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chiesi Farmaceutici S.p.A. | 32 | 2019-03-18 | 2021-10-22 |
| A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease ACT-541468, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 28 | 2018-11-15 | 2019-09-23 |
| Autologous Bronchial Basal Cell Transplantation for Treatment of COPD Bronchial basal cells - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Completed | Regend Therapeutics | 24 | 2018-06-12 | 2023-03-24 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366 CHF6366, Placebo CHF6366, umeclidinium bromide and vilanterol trifenatate - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 118 | 2017-12-28 | 2020-05-07 |
Showing 20 of 69. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (69) · Asthma (6) · Emphysema (4) · Lung Diseases (2) · Respiration Disorders (2) · Bronchiolitis (1) · Bronchitis, Chronic (1) · Cough (1) · Dyspnea (1) · Fasting (1) · Heart Failure (1) · Hypertension, Pulmonary (1) · Idiopathic Pulmonary Fibrosis (1) · Lung Diseases, Obstructive (1) · Motor Activity (1)
Chronic Disease (69) · Disease Attributes (69) · Pathologic Processes (69) · Pathological Conditions, Signs and Symptoms (69) · Respiratory Tract Diseases (69) · Lung Diseases, Obstructive (68) · Lung Diseases (67) · Bronchial Diseases (8) · Hypersensitivity (6) · Hypersensitivity, Immediate (6) · Immune System Diseases (6) · Respiratory Hypersensitivity (6) · Behavior (2) · Bronchitis (2) · Cardiovascular Diseases (2)
Budesonide (4) · Inhalation (3) · Moxifloxacin (3) · Cyclosporine (2) · Glycopyrrolate (2) · N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide (2) · Tiotropium Bromide (2) · bedoradrine (2) · tanimilast (2) · 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N,N-bis(2-methoxyethyl)hex-5-ynamide (1) · AZD-3199 (1) · AZD-8871 (1) · Beclomethasone (1) · Charcoal (1) · DNK 333 (1)
AstraZeneca (12) · Chiesi Farmaceutici S.p.A. (9) · Pearl Therapeutics, Inc. (5) · Novartis (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Mayo Clinic (2) · MediciNova (2) · Novartis Pharmaceuticals (2) · Acusphere (1) · Aeris Therapeutics (1) · Air Liquide SA (1) · Alexza Pharmaceuticals, Inc. (1) · Amgen (1) · Anhui Hemay Pharmaceutical Co., Ltd (1) · Bellerophon (1)
United States (24) · United Kingdom (14) · Germany (11) · China (8) · Belgium (4) · Bulgaria (3) · Australia (1) · Brazil (1) · France (1) · Israel (1) · Netherlands (1) · New Zealand (1) · South Africa (1)
Colin Reisner, M.D. (2) · Emma Harrop (2) · Michael Donahoe, MD (2) · Paul M. Dorinsky, MD (2) · Rainard Fuhr (2) · Stuart Mair, MD (2) · Alan W Dunton, MD (1) · Ashika Ahmed (1) · Carin Jorup, MD (1) · Darren Wilbraham, MBBS DCPSA (1) · Dave Singh, MD (1)
PMID 40391696, PMID 41677208, PMID 19436683, PMID 21474911, PMID 21615886, PMID 22075481, PMID 22927751, PMID 24168756, PMID 25027304, PMID 25060541, PMID 25383540, PMID 26050967, PMID 29856004, PMID 30425469, PMID 30982547, PMID 31539289, PMID 31841699, PMID 32071149, PMID 32253054, PMID 32907575, PMID 33152467, PMID 33511633, PMID 34600734, PMID 34620167, PMID 40466859
2018 (2), 2023 (2), 2014 (1), 2015 (1), 2016 (1), R21AT007357 (1)